Cynosure Inc. has received approval from the Food and Drug Administration for an over-the-counter device, developed with Unilever, to treat facial wrinkles.


Cynosure, Unilever, facial wrinkle device, light-based device, Michael Davin, home-use personal care market




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Unilever, Cynosure team on facial wrinkle device

July 18th, 2012

WESTFORD, Mass. – Cynosure Inc. has received approval from the Food and Drug Administration for an over-the-counter device, developed with Unilever, to treat facial wrinkles.

Cynosure said Wednesday that plans call for the light-based device, indicated for the at-home treatment of periorbital (eye) and perioral (mouth) wrinkles, to be launched commercially by Unilever in 2013.

"FDA clearance of this device marks a significant milestone in our alliance with Unilever to develop light-based devices for the consumer market," commented Michael Davin, Cynosure's president and chief executive officer. "Our strategic partnership with Unilever blends our expertise in developing market leading light-based technology that emphasizes patient safety and clinical results, with Unilever's unparalleled innovation, branded marketing and distribution."

Cynosure signed a multiyear agreement with Unilever in June 2009 to develop and commercialize light-based devices targeting the home-use personal care market.

According to the research firm Medical Insight, global sales of home-use aesthetic devices stand to grow at a compound annual rate of 12.3% from $740.4 million in 2011 to more than $1.3 billion in 2016. In North America, Medical Insight estimated, the home-use category is projected to grow by a compound annual rate of 12.1% from $451.6 million in 2011 to approximately $800 million by 2016.

Advertisement